AvMed

PHARMACY PRIOR AUTHORIZATION/STEP-EDIT REQUEST*

Directions: **The prescribing physician must sign and clearly print name (preprinted stamps not valid) on this request**. All other information may be filled in by office staff; **fax to 1-305-671-0200**. No additional phone calls will be necessary if all information (including phone and fax #s) on this form is correct. **If the information provided is not complete, correct, or legible, the authorization process can be delayed.**

Drug Requested: Zeposia® (ozanimod)

MEMBER & PRESCRIBER INFORMATION: Authorization may be delayed if incomplete.

Member Name: _____

Member AvMed #: _____ **Date of Birth:** _____

Prescriber Name: _____

Prescriber Signature: _____ **Date:** _____

Office Contact Name: _____

Phone Number: _____ **Fax Number:** _____

DEA OR NPI #: _____

DRUG INFORMATION: Authorization may be delayed if incomplete.

Drug Form/Strength: _____

Dosing Schedule: _____ **Length of Therapy:** _____

Diagnosis: _____ **ICD Code:** _____

Weight: _____ **Date:** _____

NOTE: The Health Plan considers the use of concomitant therapy with more than one biologic immunomodulator (e.g., Dupixent, Entyvio, Humira, Rinvoq, Stelara) prescribed for the same or different indications to be experimental and investigational. Safety and efficacy of these combinations has **NOT** been established and will **NOT** be permitted.

Quantity Limit: 1 capsule per day

Recommended Dosage: Oral: Initial: 0.23 mg once daily on days 1 through 4; then 0.46 mg once daily on days 5 through 7; maintenance dose: 0.92 mg once daily starting on day 8

CLINICAL CRITERIA: Check below all that apply. All criteria must be met for approval. To support each line checked, all documentation, including lab results, diagnostics, and/or chart notes, must be provided or request may be denied.

- ❑ Member has a diagnosis of **ulcerative colitis**
- ❑ Medication has been prescribed by a **Gastroenterologist**

(Continued on next page)

- ❑ Member has moderate to severe active disease with inadequate response after a **90-day** trial of **ONE** of the following conventional therapies **(verified by chart notes or pharmacy paid claims)**:
  - ❑ 6-mercaptopurine
  - ❑ aminosalicylates (e.g., mesalamine, balsalazide, olsalazine)
  - ❑ sulfasalazine
  - ❑ azathioprine
  - ❑ corticosteroids (e.g., budesonide, high dose steroids: 40-60 mg of prednisone daily)
- ❑ Member meets **ONE** of the following:
  - ❑ Member tried and failed, has a contraindication, or intolerance to **ONE** of the following **PREFERRED** biologics:
    - ❑ **ONE** of the following adalimumab products [***NOTE:** Humira NDC's starting with 83457 are not approved, NDC's starting with 00074 (MFG: Abbvie) are preferred; Hyrimoz NDC's starting with 83457 are not approved, NDC's starting with 61314 (MFG: Sandoz) are preferred]:
      - ❑ Humira®
      - ❑ Cyltezo®
      - ❑ Hyrimoz®
    - ❑ Stelara® SQ
  - ❑ Member has been established on Zeposia® for at least 90 days **AND** prescription claims history indicates **at least a 90-day supply of Zeposia was dispensed within the past 130 days (verified by chart notes or pharmacy paid claims)**

Medication being provided by Specialty Pharmacy – Proprium Rx

Use of samples to initiate therapy does not meet step edit/ preauthorization criteria.

Previous therapies will be verified through pharmacy paid claims or submitted chart notes.*